GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177
H), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA\u00ae (ustekinumab-hmny) Injection, a biosimilar referencing Stelara\u00ae (ustekinumab) Injection. STARJEMZA\u00ae is Bio-Thera's third FDA approved product.
